Absci to Participate in Upcoming Investor Conferences
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
Absci Corporation (ABSI) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
MiMedx Group (NASDAQ:MDXG) & Absci (NASDAQ:ABSI) Head to Head Analysis
Absci Q4 Earnings Call Highlights
Absci: Downgrade To 'Hold' As ABS-101 On Back Burner And Pivot To ABS-201
Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript
Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Absci Corporation (ABSI) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci Corporation (ABSI) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Absci Conference: Agentic AI Push and ABS-201 Hair-Loss Program Take Center Stage
Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer
Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026
Absci to Participate in Upcoming Investor Conferences
The Genesis Mission Has a 270-Day Timeline – And You’re Already Late
Absci Corporation (ABSI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Absci Corporation (NASDAQ:ABSI) Given Consensus Rating of “Moderate Buy” by Brokerages
The Genesis Mission Has a 270-Day Timeline – And You’re Already Late
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
10 AI Stocks Worth Buying Right Now
Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 Transcript
Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript
Absci Corporation (ABSI) Reports Q3 Loss, Lags Revenue Estimates
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
Absci to Participate in Upcoming Investor Conferences
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk
Absci Boosts AI-Powered Drug Discovery With Oracle And AMD Collaboration
Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD
Absci Expands ABS-201 Scientific Advisory Board with Addition of Leading Dermatology Experts Dr. Rodney Sinclair and Dr. David Goldberg
Absci to Participate in Upcoming Investor Conferences
Absci Corporation (ABSI) Q2 2025 Earnings Call Transcript
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025